US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...
6don MSN
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think about weight-loss drugs like Ozempic or Wegovy. (AP Video: Laura Bargfeld) ...
Ozempic is approved for the management of type ... they’re found to have unethical business practices, use deceptive advertising, or feature misrepresentative marketing of medications and ...
Midway through, there was an advertisement for Ozempic. “The persistent and widespread coverage in the media sadly compounds the overriding societal message that thin bodies are ideal ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback